MicroIslet to Webcast Presentation at Oppenheimer Diabetes Conference
September 06 2006 - 9:00AM
PR Newswire (US)
SAN DIEGO, Sept. 6 /PRNewswire-FirstCall/ -- MicroIslet, Inc.
(AMEX:MII), a biotechnology company engaged in the research,
development and commercialization of patented technologies in
transplantation therapy for people with insulin-dependent diabetes,
today announced that will present an update on the Company's islet
transplantation development strategy and progress at the
Oppenheimer & Co. Second Annual Diabetes Conference. The
conference will be held at the Jolly Hotel, Madison Towers, New
York City. MicroIslet's presentation will take place at 11:30 a.m.
Eastern time on Thursday, September 21, 2006, and will be webcast
live at:
http://www.internetvideochannel.com/oppenheimer/diabetes.asp. An
archived version of the webcast will be available until October 22.
"We are pleased to update the Oppenheimer conference attendees on
the progress we are making toward an improved diabetes treatment
paradigm," commented James R. Gavin III, M.D., Ph.D., President and
Chief Executive Officer of MicroIslet. "As we recently announced,
we have achieved long-term survival of transplanted
insulin-producing islets in ongoing studies in primates, and the
primate subjects have experienced improved glycemic control for at
least six months. Our method for islet microencapsulation
eliminates the need for chronic immunosuppression to prevent
rejection of the transplanted tissues. The transplantation site in
the peritoneum allows a minimally invasive procedure, and we have
secured access to a sufficient supply of islet tissues through our
exclusive, long-term islet supply agreement with the Mayo
Foundation for Medical Education and Research." About MicroIslet
MicroIslet is a biotechnology company engaged in the research,
development, and commercialization of patented technologies in the
field of transplantation therapy for people with insulin-dependent
diabetes. MicroIslet's patented islet transplantation technology,
exclusively licensed from Duke University, includes methods for
isolating, culturing, cryopreservation, and immuno-protection
(microencapsulation) of islet cells. MicroIslet is working to
develop and commercialize a first product, called MicroIslet-P(TM),
a microencapsulated porcine islet cell suspension that will be used
for transplantation in patients with insulin-dependent diabetes.
Additional information about MicroIslet can be found at
http://www.microislet.com/. Except for the historical information
contained herein, the matters set forth in this press release,
including the implication and interpretation of preliminary data,
the expectation of development of new therapeutic products and the
impact of MicroIslet's products on diabetes patients, are
forward-looking statements within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially,
including MicroIslet's ability to continue as a going concern, the
risks and uncertainties inherent in medical treatment discovery,
development and commercialization, the risks and uncertainties
associated with MicroIslet's early stage xenotransplantation
technologies, the risks and uncertainties of governmental approvals
and regulation, dependence on the Mayo Foundation for Medical
Education and Research as a sole source supplier of animal parts
for pre-clinical and clinical studies, MicroIslet's need to raise
substantial additional capital to proceed through human clinical
trials and bring any product to market, the risks that MicroIslet's
competitors will develop or market technologies or products that
are more effective or commercially attractive than MicroIslet's
products, and other risks detailed from time to time in
MicroIslet's most recent filings with the Securities and Exchange
Commission. These forward-looking statements speak only as of the
date hereof. MicroIslet disclaims any intent or obligation to
update these forward-looking statements. For more information,
please visit our Web site at http://www.microislet.com/. For
further information, contact: Kevin A. Hainley, MicroIslet Inc.
858-657-0287, Sean Collins, Senior Partner CCG Investor Relations
& Strategic Communications 310-231-8600 ext. 202 ISIN
US59507Q1067 DATASOURCE: MicroIslet, Inc. CONTACT: Kevin A. Hainley
of MicroIslet Inc., +1-858-657-0287, ; or Sean Collins, Senior
Partner of CCG Investor Relations & Strategic Communications,
+1-310-231-8600, ext. 202, for MicroIslet, Inc. Web site:
http://www.internetvideochannel.com/oppenheimer/diabetes.asp Web
site: http://www.microislet.com/
Copyright
Microislet (AMEX:MII)
Historical Stock Chart
From May 2024 to Jun 2024
Microislet (AMEX:MII)
Historical Stock Chart
From Jun 2023 to Jun 2024